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ABSTRACT
MicroRNAs (miRNAs) are short non-coding RNAs
that silence mRNAs. They are generated following
transcription and cleavage by the DROSHA/DGCR8
and DICER/TRBP/PACT complexes. Although it is
known that components of the miRNA biogenesis
machinery can be phosphorylated, it remains poorly
understood how these events become engaged dur-
ing physiological cellular activation. We demonstrate
that S6 kinases can phosphorylate the extended C-
terminal domain of TRBP and interact with TRBP in
situ in primary cells. TRBP serines 283/286 are es-
sential for S6K-mediated TRBP phosphorylation, op-
timal expression of TRBP, and the S6K-TRBP inter-
action in human primary cells. We demonstrate the
functional relevance of this interaction in primary hu-
man dermal lymphatic endothelial cells (HDLECs).
Angiopoietin-1 (ANG1) can augment miRNA biogen-
esis in HDLECs through enhancing TRBP phospho-
rylation and expression in an S6K2-dependent man-
ner. We propose that the S6K2/TRBP node controls
miRNA biogenesis in HDLECs and provides a molec-
ular link between the mTOR pathway and the miRNA
biogenesis machinery.
INTRODUCTION
Following their generation from theDROSHAandDICER
complexes (1), mature miRNAs associate with members of
the Argonaute (AGO) and TNRC6 (trinucleotide repeat
containing 6) families of proteins, leading to the formation
of the RNA-induced silencing complex (RISC). MiRNAs
play a central role in mammalian development (2). This
is evidenced by the fact that genetic deletion of DICER
in mice causes vascular abnormalities leading to embry-
onic lethality (3). Similarly, endothelial-specific deletion of
DICER (4,5), DROSHA (6) or AGO2 (7) impairs cell sur-
vival and responses to angiogenic stimuli. Although the re-
quirement for the miRNA biogenesis machinery in mam-
malian cell development and function has been extensively
demonstrated, a question that is significantly less explored
is whether, and to what extent, regulation of the miRNA
processing machinery occurs during human primary cell
activation. Additionally, the intracellular signalling mech-
anisms leading to post-translational modification of the
miRNA biogenesis machinery in non-transformed cells, in-
cluding DROSHA, DGCR8 (DiGeorge syndrome chromo-
somal region 8), TRBP (TARBP2; transactivating response
RNA (HIV-1)-binding protein 2) and AGO2 (8–11), re-
main poorly understood. For example, it is thought that
TRBP assists DICER-mediated precursor miRNAprocess-
ing (12,13), it controls mature miRNA length and strand
selection (14), and that it is a component of the RISC load-
ing complex (15). TRBP has three domains, the first two
of which bind dsRNA, whilst the C-terminal domain is
thought to mediate interactions with DICER and other
proteins (16–18). Paroo and colleagues demonstrated that
TRBP has two phosphorylation sites in the linker domain
between the first two dsRBDdomains (serines 142, 152) and
two at the extended third domain (serines 283 and 286) (10).
Furthermore, Kim et al. identified 10 more potential TRBP
phosphorylation sites (19). Both studies suggested that
TRBP hyper-phosphorylation controls its stability (10,19).
However, the relevance of TRBP post-translational modifi-
cations to its function in physiological responses in human
primary cells remains poorly understood.
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Here, we identify a novel mechanism controlling miRNA
biogenesis through S6 kinase (S6K)-mediated phosphory-
lation of TRBP.We show that S6 kinases phosphorylate the
extended C terminal region of TRBP (TRBP-D3). TRBP
serines 283/286 are required for in vitro TRBP-D3 phos-
phorylation, serine 283 being the predominant S6 kinase
target site. In parallel, serines 283/286 are crucial for opti-
mal TRBP expression in human primary cells.We show that
endogenous S6K1 or S6K2 interact in situ with TRBP in
primary HDLECs. Using the ANG/TIE2 signalling path-
way (20) in primary HDLECs as a model of physiologi-
cal S6K activation, we show that TRBP phosphorylation
and expression are regulated by S6K2. The ANG/TIE2
system is essential in embryonic vasculature development
and postnatal angiogenesis, and its deregulation is associ-
ated with pathological conditions such as cancer, chronic
inflammation, and cardiovascular disease (20). Function-
ally, we show that S6K2 contributes to ANG1-mediated
TRBP activation that results in enhanced expression of sev-
eral highly expressed HDLEC miRNAs. Our findings re-
veal a previously unknown molecular mechanism govern-
ing post-translational control of themiRNAbiogenesis ma-
chinery in human primary cells.
MATERIALS AND METHODS
Cell culture
HDLEC were purchased from Promocell and grown in en-
dothelial growth MV (microvascular) medium (Promocell,
catalogue number C-22020) supplemented with 10 ng/ml
VEGF-C (R&D systems; Full Media). As Basal media we
used the endothelial growth MV medium without any sup-
plements (Promocell, catalogue number C-22220). All ex-
periments were performed before passage 6. HDLECs were
seeded in either six-well plates at 8× 104 cells per well, or in
12-well plates at 1.5 × 104 cells per well and all ANG1 and
ANG2 (R&D Systems) treatments were performed at 300
ng/ml for varying times, ranging from 30 min to 24 h. HEK
293 cells were grown inDulbecco’s modifiedEagle’s medium
(DMEM), 10% Fetal Calf Serum (FCS).
siRNA transfection of primary cells
ON-TARGETplus small interfering RNA (siRNA)
oligonucleotides were purchased from Dharmacon.
HDLECs were transfected with a total of 100 nM siRNA
using TransIT-siQUEST transfection reagent (Mirus) and
Opti-MEM medium (Gibco) for 6 h before being replaced
with full endothelial growth medium. After 24 h, HDLECs
were starved for 16 h before pharmacological pre-treatment
and/or ANG1 stimulation.
Quantitative RT-PCR (qRT-PCR)
HDLEC total RNA was extracted using Qiazol and
miRNeasy RNA extraction kits (Qiagen). cDNA synthesis
of mature miRNAs was performed using Taqman miRNA
reverse transcription kits (Applied Biosystems) and mRNA
cDNA synthesis was completed using the Superscript III
reverse transcriptase (Invitrogen). qRT-PCR quantification
of DROSHA, DICER, AGO2 and PACT was performed
using Taqman gene expression assays and all mature or
primary miRNAs examined were detected using Taqman
miRNA assays (Applied Biosystems). Pri-miR-126, TRBP
andGAPDHwere quantified using the following optimized
forward and reverse primers by SYBR Green qRT-PCR
(Applied Biosystems):
pri-miR-126 forward: 5′-TATCAGCCAAGAAGGCAG
AA-3′
pri-miR-126 reverse: 5′- CGTGGCGTCTTCCAGAAT-3′
TRBP forward: 5′- GGGAAGACGCCTGTGTACGA-3′
TRBP reverse: 5′- GGTGACCCGGAAGGTGAAA-3′
GAPDH forward: 5′-GGAGTCAACGGATTTGGTCG
TA-3′
GAPDH reverse: 5′-GGCAACAATATCCACTTTACCA
GAGT-3′
Relative mRNA levels were calculated using the CT
method. mRNA and primary miRNA levels were normal-
ized to GAPDH, and mature miRNA levels were normal-
ized to U6 RNA. Absolute miRNA copy number estima-
tionswere performed using standard curves constructed fol-
lowing reverse transcription of known quantities of syn-
thetic RNA oligonucleotides (Sigma) corresponding to the
mature sequence of miR-126 and miR-16.
Proximity ligation assay
Subconfluent HDLECs were fixed in 4% (v/v)
paraformaldehyde in PBS, permeabilized in 0.3% Tri-
ton and blocked in 2% (w/v) BSA/PBS 0.05% Tween for
1 h. Primary antibodies [TRBP (Abcam, ab42018) 2.5
g/ml, S6K2 (Abnova, B02P), S6K1 (Abcam, ab119252),
2.5 g/ml, IgG Mouse (Cell Signaling) 12.5 g/ml, IgG
Rabbit (Cell Signaling) 2.5 g/ml and Dicer (Abcam) 20
g/ml)] were incubated overnight at 4◦C in blocking buffer.
Washes were performed in blocking buffer, followed by a fi-
nal wash in 10% blocking buffer/PBS. PLA was performed
using Duolink, as per the manufacturer’s instructions
(Olink Biosciences, Sigma, DUO92102). Cells were stained
for F-actin with Alexafluor 488 Phalloidin (Life Technolo-
gies, A12379) 1:40 (v/v) in blocking buffer for 20 min, and
then mounted in DAPI-containing mounting media, for
nuclear staining (Sigma, DUO82040). Images were taken
using a Zeiss LSM 510 inverted confocal microscope and
the number of PLA events per cell in 100 cells per condition
was counted.
Recombinant protein expression
Recombinant TRBP-D1/2 (residues 19–228) was gener-
ated and purified as previously reported (21). TRBP-
D3 (residues 258–366), TRBP-D3(DD) (258–366; S283D,
S286D) or PACT-D3 (208–313) were over expressed in Es-
cherichia coli BL21(DE3) as fusion proteins and purified by
immobilized metal affinity chromatography (IMAC). The
eluted fusion protein was subjected to protease cleavage and
the protein of interest separated from the fusion protein tag
by a second IMAC step. All protein samples were then fur-
ther purified by size exclusion chromatography in 20 mM
Tris pH 7.5, 200 mMNaCl, 1 mMDTT. Fractions contain-
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ing TRBP-D3, TRBP-D3(DD) or PACT-D3were identified
by SDS-PAGE and concentrated to 2 mg/ml.
In vitro kinase assay
In vitro phosphorylation of recombinant proteins were per-
formed at 30◦C in a volume of 75l in kinase reaction buffer
(25 mM Tris–HCl, pH 7.5, 0.01% Triton, 0.05 mM EGTA,
0.5 mM sodium orthovanadate, 5 mM -glycerophosphate,
2.5 mM DTT and 10 mM MgCl2), with 160 nM active
recombinant S6K1, S6K2, AKT1 or ERK2 (Invitrogen)
and 66 M TRBP-D3, TRBP-D3(DD), TRBP-D1/D2 or
PACT-D3. Reactions were initiated by the addition of 20
Ci [ -32P]ATP and unlabelled ATP to a final concentra-
tion of 250 M. Aliquots of 15 l were removed at 0, 1, 2, 3
and 4 h and the reactions terminated by the addition of 2×
sodium dodecylsulphate (SDS) sample buffer. Incorpora-
tion of 32P was quantified by resolving the reactions on 15%
sodium dodecylsulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gels, staining the gel withCoomassie, excis-
ing the bands corresponding to the substrates and then sub-
jecting them to liquid scintillation counting. To normalise
the 32P incorporation to protein content, the intensity of
Coomassie staining for each substrate bandwas determined
by densitometry.
Mass spectrometry
Following in vitro phosphorylation, the reactions were
quenched by the addition of 50l SDS loading buffer. Sam-
ples were run on a 15% SDS-PAGE gel, 20 l per lane,
and stained with Coomassie. Protein bands were excised
from the gel, destained, reduced, alkylated and digested
with trypsin following standard protocols. The resulting
peptide solutions were enriched for phosphopeptides using
TiO2 micro-columns. Following enrichment, samples were
spotted directly onto the MALDI target plate in DHB ma-
trix (20 mg/ml 2,5-dihydroxybenzoic acid, 1% phosphoric
acid). MS/MS analysis was performed on a Bruker Ultra-
flex in positive ion, reflector mode. MS spectra were ac-
quired in the mass range m/z 800–4000. Peaks of inter-
est on the MS spectra for each sample were then selected
for MS/MS analysis. The MS/MS data was submitted to
database searching against an in-house database, using a lo-
cally running copy of theMascot software (Matrix Science)
through a Biotools (Bruker Daltonics) interface.
Western blotting and co-immunoprecipitation assays
HDLEC protein was extracted using RIPA buffer: 150 mM
NaCl; 10 mM Tris–HCl pH 7.2; 0.1% SDS; 0.1% Triton X-
100; 1% sodium deoxycholate; 5 mM EDTA; 1% protease
(P8340) and phosphatase inhibitors 2 (P5726) and 3 (P0044)
cocktails (all inhibitor cocktails purchased from Sigma).
Equal total amounts of protein were resolved on polyacry-
lamide gels. Antibodies against TIE2 (#4224, AB33), phos-
pho (#4370, D13.14.4E) and total ERK (#4695, 137F5),
phospho (Ser473, #4060, D9E; Ser308, #2965, C31E5) and
total AKT (#4691, C67E7), phospho (#2974) and total
mTOR (#2983, 7C10), phospho-S6K1 (#9234, 108D2) and
total S6K1 (#2708, 49D7), total S6K2 (#14130), DICER
(#5362, D38E7), DROSHA (#3364, D28B1), phospho
(#4858, D57.2.2E) and total S6RP (#2217, 5G10) and
AGO (#2897, C34C6) were purchased from Cell Signaling
Technology. Antibodies to PACT (PRKRA) (ab31967) and
-actin (ab6276) were purchased by Abcam. Antibodies to
TRBP were purchased from Abcam (ab42018) and Pro-
teintech (15753-1-AP). Reactivity was detected with HRP-
conjugated secondary antibodies and quantified by ECL
(GE Healthcare) or Clarity ECL (Bio-Rad). Densitometry
was performed using ImageJ software.
For co-immunoprecipitation of ectopically expressed
proteins, subconfluent HEK293 cells were lysed by the ad-
dition of ice-cold lysis buffer (Cell Signaling Technology,
#9803, 20 mM Tris (pH 7.5), 150 mMNaCl, 1 mM EDTA,
1 mMEGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM -glycerophosphate, 1 mMNa3VO4, 1 g/ml
Leupeptin, adding 1 mM PMSF immediately prior to use).
Lysates were incubated for 10 min on ice and centrifuged
at 13 000 rpm for 10min. The lysate was then pre-cleared
with rabbit IgG (Cell Signaling Technology, #2729) for 2 h
at 4◦C followed by incubation with protein A beads (#8687)
for 20 min at room temperature. The cleared lysates were
incubated with 1 g anti-S6K2 (#14130) or normal IgG
(#2729) for 16 h at 4◦C. The immune complexes were incu-
bated with protein A beads (#8687) for 20 min, washed 5
times, and eluted in 40 l 4× SDS-PAGE sample buffer.
Phosphatase treatment of cell lysates
Protein extracts were prepared as before, except cells were
lysed in modified RIPA buffer lacking EDTA, but supple-
mented with protease and phosphatase inhibitor cocktails
(for control samples) or protease inhibitor cocktail alone
(for samples to be phosphatase treated). For  phosphatase
treatment, soluble protein lysates (10 g) were incubated
with or without  phosphatase (400 U; NEB) for 45 min
at 30◦C.
Lentiviral cloning and transduction of HDLECs
TRBP (TARBP2, NCBI Reference Sequence
NM 134323.1) amplified from HDLEC cDNA and
subcloned into the pSIN lentiviral vector using the NotI
and BamHI restriction enzymes and the following primers:
Forward: TRBP BamH1 = 5′-cgcggatccATGAGTGAA
GAGGAGCAAGGC-3′
Reverse TRBP Not1 = 5′-aaggaaaaaagcggccgcCAGCTG
GGGCTTCACTTG-3′
For lentiviral transduction, virions were produced in
HEK293T cells as described previously (22). Site-directed
mutagenesis was performed using the QuickChange Strata-
gene kit following manufacturers’ instructions. HDLECs
were infected with TRBP-WT, TRBP-AA, TRBP-DD
lentiviruses 72 h before analysis. For HEK293 infections,
106 cells were infected with 1–2 ml of indicated lentiviruses
and cells were grown until 80% confluency before being har-
vested for immunoprecipitation experiments.
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MicroRNA profiling of HDLEC
MicroRNA profiling was performed using Agilent miRNA
chips v19.0, containing 60,180 probes for 2006 miRNAs.
Four replicates of ANG1-treated and control HDLECs
were compared after 24 h treatment. Following quality con-
trol, raw data import and normalization together with dif-
ferential expression analysis were performed using the R
Bioconductor software package limma (23). The signal in-
tensity of each probe on each array was quantified by taking
the median foreground signal with no background correc-
tion. Subsequently all arrays were filtered to remove con-
trol probes and were normalized using the quantile method,
which sets intensities to have the same empirical distribu-
tion across arrays. The differential analysis was performed
using a moderated t-statistic computed for each contrast
for each probe. This analysis was performed on the whole
dataset taking the mapping into account as previously de-
scribed (23). In Figure 1B, detectable miRNAs were identi-
fied using an arbitrary cut-off point of 6.4 for normalized
signal (Supplementary Table S1). This cut-off point allows
inclusion of lowly expressed (50–100 copies per cell) but de-
tectable miRNAs (e.g. miR-132 (24)).
Statistical analysis
All experiments were performed as independent replicates
(n≥ 3) and are illustrated asmeans including error bars cor-
responding to standard deviation from the mean (SD). P-
values were calculated using Student’s t-test when only com-
paring to a negative control sample, one-wayANOVAwhen
performing multiple comparisons between conditions (one
class), and two-way ANOVA when performing multiple
comparisons between different conditions (two classes, e.g.
Figure 7D). The statistical significance of ANG1-induced
miRNA expression enhancement (Figure 7A) was calcu-
lated using a chi-square test against the null hypothesis that
there was no bias towards up- or down-regulation (i.e. half
the miRNAs show a positive FC and the half negative FC).
A P-value <0.05 was considered significant.
RESULTS
TRBP serines 283/286 are required for optimal TRBP ex-
pression in human primary cells and in vitro phosphorylation
of TRBP-D3 by S6 kinases
Weobserved that two previously identified (10) TRBPphos-
phorylation sites (S283, S286) in the extended third, non-
canonical dsRBD of TRBP (TRBP-D3) displayed features
of potential S6 kinase substrate motifs (RXXS, Figure 1A)
(25,26). This motif is not observed for any of the other
twelve candidate TRBP phoshorylation sites (10,19), nor
in the equivalent domain of PACT (PACT-D3), a TRBP
homologue and DICER co-factor with two known phos-
phorylation sites (27,28) in its third domain (Figure 1B).
As S6 kinases play a central role in eukaryotic translation
we pursued this potential link to miRNA biogenesis fur-
ther. In vitro kinase assays demonstrated that TRBP-D3 can
be phosphorylated by S6K1, S6K2, but also AKT1 (Figure
1C), inferring that, at least in vitro, this domain can be an
AGC kinase substrate (25,26). S6K2 and AKT1 had nearly
undetectable kinase activity when a TRBP mutant (TRBP-
D3(DD), in which the two candidate serines were mutated
to aspartate and thus could not be phosphorylated, was
used as a substrate. S6K1 demonstrated some residual ac-
tivity against TRBP-D3(DD) possibly due to other serines
present in the domain. No S6K-mediated phosphorylation
was observed when using TRBP-D1/2, a construct con-
taining the two N-terminal dsRBDs of TRBP (Figure 1D).
ERK2 was used as a control and was able to phosphorylate
TRBP-D1/2 as reported previously (10). Similarly, S6K2
did not show any detectable reactivity with PACT-D3 (Fig-
ure 1E). Consistent with the observed AGC kinase binding
motif and the above results, mass spectrometry analysis of
in vitro phosphorylated TRBP-D3 confirmed that at least
serine 283 is directly phosphorylated by AGC kinases (Sup-
plementary Figure S1A).
Next, we tested the functional relevance of serines
283/286 in cells. To provide physiological relevance of our
findings, we utilized human primary cells rather than trans-
formed cell lines, using primary HDLECs as a model sys-
tem. We transduced HDLECs with lentiviral vectors en-
coding for full-length wild-type TRBP (TRBP-WT) or with
mutants in which serines 283 and 286 have been mutated
to alanines or aspartate (TRBP-AA or TRBP-DD, respec-
tively). We titrated the three constructs into HDLECs and
performed Western blot analyses (Figure 2A). The slower
migrating TRBP band has been previously shown to corre-
spond to hyper-phosphorylated TRBP (TRBP phosphory-
lated at multiple sites) (10,19). We confirmed that this band
was sensitive to phosphatase treatment (from now on re-
ferred to as ‘phosphorylatedTRBP’; p-TRBP inFigure 2B).
During these titration experiments we ensured that TRBP
mRNA levels were comparable betweenWTandTRBPmu-
tants and found that TRBP expression in HDLECs was
reduced when the two serines were mutated to alanines
(Figure 2C) demonstrating that optimal TRBP expression
and/or folding are directly linked to these two residues. Lev-
els of phosphorylated TRBP increased following transduc-
tion of cells with increasing amounts of TRBP-WT, reach-
ing a plateau for the highest amount of virus used (Figure
2A). When serines 283 and 286 were mutated to aspartate
to mimic constitutive phosphorylation of these residues,
there was an enhancement in p-TRBP/TRBP ratios at low
lentivirus volumes (before the p-TRBPplateauwas reached;
Figure 2A and D; compare 50 and 100 l virus lanes for
TRBP-WT and TRBP-DD TRBP), but we did not observe
an enhancement beyond that plateau. One possible expla-
nation for this could be that when introducing high TRBP
amounts in HDLECs, the abundance of hyperphosphory-
lated TRBP becomes limited by the amounts of kinases in
these cells. Single mutation of serine 283 to alanine also neg-
atively affected TRBP protein levels, whereas no differences
were observed upon single mutation of serine 283 to aspar-
tate (Supplementary Figure S1B and C).
Having shown that S6K2 and S6K1 can phosphory-
late TRBP-D3 in vitro and that TRBP Ser283 and Ser286
contributed to optimal TRBP expression in primary cells,
we investigated whether these kinases interact with TRBP
in HDLECs. To determine potential endogenous inter-
actions in primary cells, we used proximity ligation as-
says (PLAs) (29). We found that under optimal steady-
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Figure 1. TRBP-D3 is a substrate of S6 kinases. (A) Alignment of candidate S6K phosphorylation sites on TRBP and known sites on S6RP (shown in
green). Amodel S6K substrate peptide is also shown for reference. Two validated S6K substrates containing the RXRXXS orRXXS consensusmotifs (R in
purple) are also shown. (B) TRBP-D3 (aa258-366) and PACT-D3 (aa208–313) sequence alignment, illustrating known TRBP and PACT phosphorylation
sites (green). (C) [ -32P] autoradiogram and total protein (detected by Coomassie staining) after kinase assay incubation (4 h) of TRBP-D3 and TRBP-
D3(DD) with active S6K1, S6K2, or AKT1. (D) [ -32P] autoradiogram and total protein (detected by Coomassie staining) after kinase assay incubation
(4 h) of TRBP-D1/D2 with recombinant S6K1, S6K2, AKT1 or ERK2. A band shift due to ERK phosphorylation is observed for TRBP-D1/D2. (E)
[ -32P] counts for TRBP-D3 and PACT-D3 during 4 h in vitro phosphorylation by recombinant S6K2.
state growth conditions (HDLECs growing in fully supple-
mented media––see Materials and Methods), endogenous
S6K2 and TRBP directly interact in situ in HDLECs (Fig-
ure 3A, and SupplementaryFigure S2). TheTRBP/DICER
interaction served as a positive control for the PLAs (Figure
3B). In addition to endogenous S6K2, our PLA analyses in-
dicated that S6K1 can also interact with TRBP inHDLECs
under steady state growth conditions (Figure 3C and D).
S6K2 controls TRBP phosphorylation and expression in ac-
tivated HDLECs
To further investigate the significance of the TRBP/S6K2
interaction we exploited a well-characterized model of pri-
mary HDLEC activation and determined the effect of
ANG1 and ANG2 on TRBP expression. Following incu-
bation of subconfluent HDLEC cultures with ANG1 or
ANG2, or both (18–24 h), we observed that ANG1 can in-
duce a modest and reproducible increase in TRBP phos-
phorylation (Figure 4A, corresponding to the top band
in TRBP immunoblots) and total TRBP expression (bot-
tom band and lower exposure in TRBP immunoblots in
Figure 4A). The ANG1 effect on TRBP phosphorylation
was also confirmed using a different anti-TRBP antibody
(Supplementary Figure S3A). These findings for endoge-
nous TRBP were in agreement with biochemical and ex-
ogenous over-expression studies demonstrating that lev-
els of TRBP phosphorylation control its stability and can
correlate with total TRBP expression (10). The effect of
ANG1 on hyperphosphorylated TRBP levels was reversed
by ANG2, which is known to act as a TIE2 antagonist
when added in endothelial cell cultures (20). ANG1-treated
HDLECs demonstrated a statistically significant increase of
AGO2 levels but no changes in levels of PACT, DICER,
and DROSHA (Supplementary Figure S3B, S3C). ANG1
treatment did not affect TRBP mRNA levels, demonstrat-
ing that TRBP was not transcriptionally regulated under
these conditions (Supplementary Figure S3D). TIE2 stim-
ulation activates the ERK and AKT pathways (20) and
the ERK pathway has already been linked to phosphory-
lation of TRBP serines 142 and 152 (10). In agreement with
this, ANG1-induced phosphorylation of TRBP was depen-
dent on TIE2 and ERK1/2 (Supplementary Figure S3E).
The observed TIE2 downregulation in ANG1-treated cells
is due to the previously reported activation-induced recep-
tor internalization and degradation (30).
Next, we investigated whether S6K1 and S6K2 were also
involved in ANG1 induced TRBP phosphorylation. By
measuring levels of S6RP phosphorylation, a known sub-
strate of S6 kinases, we confirmed that these kinases were
active in HDLECs up to 24 h of ANG1 treatment (Fig-
ure 4B). As before, ANG1 treatment for 24 h resulted in
increased TRBP phosphorylation. S6K1 knockdown en-
hanced TRBP phosphorylation and expression in both con-
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Figure 2. TRBP serines 283/286 control TRBP expression and post-translational modification. (A) Phosphorylated (p-TRBP) and total TRBP expression
in HDLECs transduced (3 days, full media; see Materials and Methods) with the indicated volumes of lentiviruses (per 80 000 cells) encoding for TRBP-
WT, TRBP-AA and TRBP-DD mutants. The top two rows of the immunoblots correspond to high (10–15 min) and low (1 min) exposure of the TRBP
immunoblot, respectively. The band corresponding to hyper-phosphorylated TRBP is indicated as pTRBP. (B) Immunoblots showing TRBP and phos-
phorylated TRBP and phosphorylated ERK1/2 after lamda () phosphatase treatment of HDLEC protein lysates. (C) Graph showing TRBP mRNA and
protein levels for HDLECs transduced with 50, 100, 200, and 400 l TRBP-WT, TRBP-AA, and TRBP-DD lentiviruses (per 80 000 cells, see Figure 7A).
Levels are shown as fold induction compared to endogenous TRBP levels (no virus). (D) Graph showing the ratio of phosphorylated to total TRBP against
TRBP mRNA levels for HDLECs transduced with TRBP-WT, and TRBP-DD lentiviruses. Levels are shown as fold induction compared to endogenous
TRBP levels (no virus).
trol and ANG1-treated cells. However, in S6K2 deficient
HDLECs, the ANG1-induced TRBP phosphorylation and
expression were impaired (Figure 4B and Supplementary
Figure S4A). Of note, ANG1 did not induce TRBP phos-
phorylation in HDLECs lacking S6K1 and S6K2, with
only minimal effects on total TRBP expression (Figure
4B, and Supplementary Figure S4A), demonstrating that
S6K2 knockdown in S6K1-depleted cells specifically af-
fected TRBP phosphorylation. Depletion of S6 kinases did
not affect TRBP mRNA levels (Figure 4C). Both of these
kinases are mTOR substrates and previously reported to be
downstream of the AKT and ERK pathways, which are ac-
tivated downstream of TIE2 (31,32). We observed mTOR
and AKT activation after 24 h treatment of HDLECs with
ANG1 (Figure 4B). ERK was not activated at this time-
point but we confirmed that it was activated at the early
stages of ANG1 addition (Supplementary Figure S4B and
(33)). Pre-treatment of HDLECs with Rapamycin resulted
in reduction of TRBP phosphorylation and expression in
ANG1-treated HDLECs (Supplementary Figure S4C), in
agreement with mTOR controlling S6K activation. The ef-
fects of S6 kinases on TRBP were in agreement with S6K1,
but not S6K2, mediating negative feedback loops affecting
mTOR/AKT signalling (34,35). Indeed, we observed en-
hanced AKT activation in HDLECs lacking S6K1 (Figure
4B). Neither S6K2, nor S6K1 depletion affected phospho-
rylated ERK levels at 24 h (Figure 4B).
To further investigate the interaction of TRBPwith S6Ks
and dissect the differential effects of S6K1 and S6K2 on
TRBP, we determined whether endogenous TRBP and
S6Ks interact during ANG1 activation. We found that
S6K2 and TRBP interacted in untreated HDLECs but the
interaction was dramatically increased at 12 h post ANG1
addition (Figure 5A, B and Supplementary Figure S5A).
There were no differences in TRBP phosphorylation and
expression at 12hrs post ANG1 addition (Supplementary
Figure S5B). The S6K2/TRBP interaction was also above
background levels at 30min followingANG1 addition (Fig-
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Figure 3. Endogenous TRBP interacts with S6Ks in primary HDLEC. (A) Analysis of TRBP and S6K2 interaction by PLA (red) in HDLECs growing in
full growth factor media. Nuclei (blue) and F-actin (green) staining are also shown (scale bar: 10 m). PLA events (in red) are indicated with yellow arrows.
(B) Analysis of TRBP andDICER interaction by PLA (red) in HDLECs growing in full growth factor media. PLA events (in red) are indicated with yellow
arrows. (C) Histogram of TRBP/S6K2 PLA events per cell detected in HDLECs cultured in full growth factor media. (D) Histogram of TRBP/S6K1 PLA
events per cell detected in HDLECs cultured in full growth factor media.
ure 5A and B). Rapamycin pre-treatment significantly pre-
vented the S6K2 and TRBP interaction (Figure 5C). No-
tably, the S6K1/TRBP interaction failed to exceed the lev-
els observed in control cells during ANG1 treatment of
HDLECs (Figure 5D) at time-points we observed maxi-
mal S6K2/TRBP interaction. This indicated that although
both S6 kinases are capable of phosphorylating TRBP-D3
in vitro (Figure 1C), S6K2 is the predominant S6 kinase that
associates with TRBP under these conditions.
Having found that HDLEC activation resulted in in-
creased association of S6K2, but not S6K1, with TRBP,
we tested the effect of disrupting the AGC kinase-binding
TRBP motif on the S6K2/TRBP interaction in cells. We
transduced HDLECs with full-length TRBP-WT, TRBP-
AA, andTRBP-DD lentiviruses, using appropriate volumes
to achieve equal TRBP protein expression for all constructs.
Using these cells, we found that the interaction of TRBP-
WT with endogenous S6K2 was readily detectable. How-
ever, the TRBP/S6K2 PLA levels were significantly lower
inHDLECs over-expressing TRBP-AAor TRBP-DD (Fig-
ure 6A, B and Supplementary Figure S6). The interac-
tion between S6K2 and TRBP-DD was the weakest, sup-
porting a model where TRBP phosphorylation at serines
283/286 promotes dissociation of TRBP from S6K2. This
model was also consistent with the observation that maxi-
mum S6K2/TRBP interaction in ANG1-treated HDLECs
(12hrs) preceded the peak of TRBP phosphorylation (24
h). Note that as over-expression experiments were per-
formed in the presence of endogenous TRBP, some levels
of S6K2/TRBP interaction were expected and observed in
all conditions. To further validate these findings in a dif-
ferent cellular context, we overexpressed S6K2, TRBP-WT,
and TRBP-DD in HEK293 cells and showed that TRBP-
WT, but not TRBP-DD co-immunoprecipitates with S6K2
(Figure 6C and D). These experiments indicated that the
S6K2/TRBP interaction ismediated through direct binding
of the kinase to the TRBP phosphorylation motif (Figure
1A).
TRBP and S6K2 contribute to enhanced miRNA expression
in ANG1-treated HDLECs
To determine the effect of ANG1 treatment on the HDLEC
miRNA transcriptome, we performed miRNA profiling of
control and ANG1-treated HDLECs (Supplementary Ta-
ble S1). We observed that there was a statistically signifi-
cant shift (P = 2.3 × 10−5) towards up-regulation for all
detectable miRNAs (demonstrated as a positive log fold
change for 276 miRNAs with average normalized signal
>6.4; Figure 7A). We did not observe any expression shift
when all miRNA probes present on the slides were included
in the analysis confirming that signal normalization was
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Figure 4. S6K2 is required for ANG1-mediated TRBP activation in HDLECs. (A) TRBP and p-TRBP levels in 24 h ANG stimulated HDLECs. Bar graph
shows relative TRBP and p-TRBP levels in 24 hANG stimulatedHDLECs by densitometry. Values are normalized to cells grown in basal media (no growth
factors) and are illustrated as mean ± SD (n = 3). P values are shown (*P < 0.05; **P < 0.01). (B) Levels of indicated total and phosphorylated proteins
in control (–) and ANG1-stimulated (+) HDLECs (24 h) transfected with non-targeting control (NTC), S6K1, S6K2 and dual S6K1/S6K2 siRNAs. (C)
TRBP mRNA levels in HDLECs transfected with non-targeting control (NTC), S6K1, S6K2, and grown without growth factors (Basal) or with ANG1
for 24 h.
robust (Supplementary Figure S7A). Notably, the propor-
tion of miRNAs showing a positive fold change (FC) in-
creased with increasing miRNA expression (Supplemen-
tary Figure S7A). To confirm that this was a true shift
we tested the effect of ANG1 on expression of 14 ma-
ture miRNAs by qPCR. Seven of these miRNAs (miR-
126, miR-21, miR-16, miR-29a, miR-221, miR-210 and
miR-132) showed statistically significantly higher expres-
sion in ANG1-treated HDLECs (Figure 7B, and Supple-
mentary Figure S7B). None of the testedmiRNAs showed a
statistically significant down-regulation upon ANG1 treat-
ment. Furthermore, we confirmed that ANG1 had a signif-
icant effect on absolute copy number of two highly abun-
dant miRNAs (miR-126 and miR-16; Supplementary Fig-
ure S7C, S7D). As in the case of TRBP phosphorylation
(Figure 4A), the effect of ANG1 on miRNA expression
was antagonized by concurrent addition of ANG2 (Sup-
plementary Figure S7E). Notably, we did not observe any
differences in levels of the primary transcripts of ANG1-
regulated miRNAs (Figure 7C), indicating that ANG1 af-
fected post-transcriptional miRNA regulation. These re-
sults demonstrated that ANG1 treatment had a widespread
positive effect on miRNA expression in primary HDLECs
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Figure 5. S6K2, but not S6K1, interacts with TRBP during ANG1 treatment of HDLECs. (A) Analysis of TRBP and S6K2 interaction by PLA (red) in
HDLECs during 24 h ANG1 stimulation. Nuclei (blue) and F-actin (green) staining are presented in addition (scale bar: 10 m). PLA events (in red) are
indicatedwith yellow arrows. (B) Bar graph illustratingmean number of TRBP/S6K2PLA events detected inHDLECs cultured in basalmedia or following
overnight growth factor withdrawal and post 30 min, and 2, 12 and 24 h ANG1 stimulation. (C) Bar graph illustrating mean number of TRBP/S6K2 PLA
events detected in HDLECs pre-treated with DMSO or Rapamycin (10 nM) for 2 h prior to 30min and 24 h ANG1 stimulation. (D) Bar graph illustrating
mean number of TRBP/S6K1 PLA events detected in HDLECs cultured in Basal media or following overnight growth factor withdrawal and post 30 min,
or 12 h ANG1 stimulation. Values presented are means ± SD. P values are shown (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 6. TRBP serines 283/286 are essential for the TRBP/S6K2 interaction in HDLECs. (A) PLA analysis of TRBP and S6K2 in HDLECs transduced
with TRBP-WT (150ml/80 000 cells), TRBP-AA (600ml/80 000 cells), and TRBP-DD lentiviruses (200ml/80 000 cells). The used volumes were calculated
and verified to ensure equal TRBP protein expression between WT and mutant TRBP proteins. Nuclei (blue) and F-actin (green) staining are also shown
(scale bar: 10 m). PLA events (in red) are indicated with yellow arrows. B. Dot plot illustrating mean number of TRBP/S6K2 PLA events detected under
the same conditions with (A). Values presented are means ± SD. P values are shown (*P< 0.05; ***P< 0.001). (C) Co-immunoprecipitation of S6K2 and
TRBP in HEK293 cells over-expressing S6K2 and TRBP. Cells were transduced with S6K2 and TRBP-WT or TRBP-DD lentiviruses and harvested for
immunoprecipitations when 80% confluent. (D) Quantification of co-immunoprecipitated TRBP with S6K2 in cells overexpressing TRBP-WT or TRBP-
DD.
and that for all the tested miRNAs this effect was post-
transcriptional.
We then tested if the observed increase in TRBP phos-
phorylation and expression in ANG1-treated HDLECs
(Figure 4A) contributes to the increased expression of
ANG1-regulated miRNAs. As the effect of ANG1 on
TRBP expression was modest we partially depleted TRBP
in HDLECs and this ablated the effect of ANG1 on
miRNA expression (Figure 7D). TRBP depletion also af-
fected miRNA expression in HDLECs growing in full
growth factor supplemented media and in cells growing in
the basal media (absence of growth factors; Supplemen-
tary Figure S7F). Furthermore, we found that in HDLECs
grown in basal media, TRBP overexpression was suffi-
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Figure 7. ANG1 enhances HDLECmiRNA expression in a TRBP- and S6K2-dependent manner. (A) Dot plot of miRNA log average expression against
log fold change (FC) for all detectable miRNAs in HDLECs (average normalized signal ≥ 6.4). Percentages of down-regulated (negative log FC) and
up-regulated (positive log FC) are shown. (B) Mature miRNA expression in control and 24 h ANG1 stimulated HDLECs determined by qRTPCR. Values
are illustrated as mean ± SD (n = 4–6). (C) Primary miRNA transcript levels in 24 h Basal media, ANG1 and/or ANG2 treated HDLECs relative to
cells grown in full growth factor containing media (n = 3). (D) Relative HDLEC miRNA expression in control and TRBP siRNA transfected cells post
24 h ANG1 stimulation or culture in Basal media. Immunoblot indicating knockdown levels also shown as insert. (E) miRNA expression in 24 h ANG1
stimulated HDLECs that had been transfected with S6K1 and/or S6K2 siRNAs. miRNA expression data shown is relative to control siRNA transfected
HDLECs that had been stimulated for 24 h with ANG1. (F) miRNA expression in 24 h ANG1 stimulated HDLECs that had been transfected with control
(NTC) or S6K2 siRNAs and lentiviruses encoding for TRBP-WT, TRBP-DD, and TRBP-AA (appropriate volumes of lentiviruses were used to achieve
equal expression of WT and mutant TRBP). For each miRNA, expression levels shown are relative to the average expression of this miRNA amongst the
eight tested samples shown in x-axis. Values presented are means ± SD. P values are shown (*P < 0.05; **P < 0.01; ***P < 0.001).
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cient to increase miRNA expression (Supplementary Fig-
ure S7G). These findings indicated that under these condi-
tions (growth factor starvation) TRBP levels become limit-
ing, and increasing TRBP expression through overexpres-
sion (Supplementary Figure S7G) or ANG1 stimulation
(Figure 4A) could result in increased miRNA expression.
Depletion of S6K2 resulted in a significant reduction in
expression of miRNAs that were induced by ANG1 (miR-
126, miR-16, miR-210, miR-21, miR-221 and miR-132, see
Figure 7B) in ANG1-treated HDLECs (Figure 7E). In con-
trast, S6K1 depletion induced an increase in expression of
the tested miRNAs, whereas levels of all tested miRNAs
were reduced in S6K1/S6K2 depleted HDLECs in com-
parison to S6K1-depleted cells (Figure 7E). These results
were consistent with the effects of S6K depletion on TRBP
phosphorylation and expression (Figure 4B) and the effect
of TRBP depletion on these miRNAs (Figure 7D). The sta-
tistically significant negative effect of S6K2 depletion on the
expression of all tested miRNAs was not observed upon
reintroduction of TRBP (Figure 7F), which at least par-
tially rescued expression of all tested miRNAs. Exogenous
expression of TRBP-AA or TRBP-DD (adjusted to achieve
same TRBP expression levels) also partly rescued the effect
of S6K2 depletion on miRNA expression. This suggested
that, in ANG1-treated HDLECs, the predominant effect of
S6K2-mediated TRBP phosphorylation is maintainance of
optimal TRBP expression and miRNA abundance.
DISCUSSION
Using human primary cells, we describe a previously
uncharacterized S6K2-mediated mechanism controlling
miRNA biogenesis in human primary cells, through regu-
lation of TRBP phosphorylation and expression (Supple-
mentary Figure S7H). Phosphorylation of TRBP-D3 by S6
kinases is a regulatory mechanism specific to TRBP and
does not affect PACT, revealing a significant difference be-
tween the signal transduction mechanisms regulating the
twoDICER co-factors. In endothelial cells, this mechanism
can be engaged through TIE2, a receptor tyrosine kinase
with central roles in development, homeostasis, and patho-
logical function of endothelium (20). This provides novel in-
sight into how changes in the extracellular environment can
affect intracellular miRNA biogenesis rates during blood
and lymphatic vessel formation.
We demonstrate that growth factor-mediated TRBP ac-
tivation can lead to significant and widespread changes in
miRNA expression (Figure 7). The impact of ANG1 on
HDLEC miRNA expression should be placed in the con-
text of the described experimental conditions and previ-
ous reports demonstrating that ANG1 has anti-apoptotic
and pro-proliferative effects on endothelial cells (36–38).
Upon growth factor withdrawal, HDLECs are under apop-
totic stress. ANG1 increases expression of some of the most
highly expressed miRNAs in HDLECs (e.g. miR-126, miR-
21, miR-16), for which a 1.2–1.5-fold enhancement corre-
sponds to thousands of miRNA copies per cell. Concurring
with previous reports proposing that the miRNA signature
of a cell confers robustness during responses to stress (39)
and that themiRNA-silencingmachinery is required for en-
dothelial cell survival (4–7), we speculate that the ANG1-
mediated enhancement of miRNA expression might con-
tribute to its pro-survival effects in endothelial cells.
The effects of ANG1 on HDLECmiRNA expression are
achieved through regulation of TRBP phosphorylation and
expression by S6 kinases. TRBP phosphorylation at 18 –
24h post ANG1 stimulation, is driven by S6 kinases and
not ERK, which is not activated above background levels at
these stages (Figure 4) but is still required for optimal TRBP
activation (Supplementary Figure S3E). This suggests that
ERK and S6 kinases collaborate to induce TRBP activation
followingANG1 stimulation.Given the previously reported
link between ERK and S6K activation (40), we should note
that it is plausible that ERK can affect phosphorylation of
TRBP indirectly through activating S6K2. Our findings are
consistent with a phosphorylation-induced substrate disso-
ciation model (41,42), suggesting that activated S6K2 phos-
phorylates TRBP,which then dissociates fromS6K2 to bind
DICERand enhancemiRNAprocessing (Figures 1C, 5 and
6, Supplementary Figure S5).
We demonstrate that S6K1 and S6K2 play non-
redundant and critical roles in the regulation of TRBP and
miRNA expression in adult human endothelial cells. Al-
though they share several common substrates and activities,
non-redundant activities for the two S6 kinases have been
previously reported (43,44). For example, S6K2, but not
S6K1, controls cell proliferation in cancer cell lines (45,46).
The differential effects of the two kinases in the context of
TRBP activation in ANG1-treated HDLECs (Figure 4B)
are due to the fact that the two kinases participate in dis-
tinct feedback regulatory loops (35), and can display dis-
tinct subcellular localization patterns (47). Indeed, during
ANG1 treatment of HDLECs, TRBP is found in the prox-
imity of S6K2 at significantly higher levels than those ob-
served in control cells, however this is not the case for S6K1
and TRBP (Figure 5). Furthermore, depletion of S6K1 re-
sults in compensatory activation of signalling pathways (e.g.
increased AKT activation; Figure 4B), while S6K2 depel-
tion does not have this effect. However, as TRBP-D3 can be
phosphorylated by both kinases in vitro (Figure 1C), our re-
sults do not exclude the possibility that TRBP phosphoryla-
tion can be predominantly S6K1-dependent in other growth
conditions or cellular contexts.
Implicating S6 kinases in the regulation of miRNA
biogenesis can have far-reaching implications. We spec-
ulate that regulation of mature miRNA levels through
mTOR/S6K-mediated TRBP regulation is likely to be in-
volved in other, non-endothelial, contexts of cellular activa-
tion. Through identifying TRBP as a novel S6K substrate,
we provide a mechanism that links the mTOR pathway to
miRNA biogenesis. We speculate that this is a fundamen-
tal mechanism co-ordinatingmRNA translation andRNA-
mediated silencing in mammalian cells.
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